Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.

Paz-Ares, Luis; Luft, Alexander; Vicente, David; Tafreshi, Ali; Gümüş, Mahmut; Mazières, Julien; Hermes, Barbara; Çay Şenler, Filiz; Csőszi, Tibor; Fülöp, Andrea; Rodríguez-Cid, Jerónimo; Wilson, Jonathan; Sugawara, Shunichi; Kato, Terufumi; Hyeong Lee, Ki; Cheng, Ying; Novello, Silvia; Halmos, Balazs; Li, Xiaodong; M Lubiniecki, Gregory; Piperdi, Bilal; M Kowalski, Dariusz; Investigators, KEYNOTE-407

doi:10.1056/nejmoa1810865

Public

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.

Published in The New England journal of medicine • Nov 22, 2018

NobleIDark:/48914/w1/20260526/BD0382D2Record on NobleID

Authors:

Luis Paz-Ares

,

Alexander Luft

,

David Vicente

Abstract

BACKGROUND: Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to sig...

Discussions